InsiderClue
Stocks · Health care · Pharmaceutical Preparations

MIRA PHARMACEUTICALS, INC.

MIRA Clue Score38
United States CIK 0001904286
$0.75 +6.05% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.75 −82.78% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 3 Aug 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2022Net income−7.1EPS, diluted−0.40Fiscal year 2023Net income−12.0EPS, diluted−0.85Fiscal year 2024Net income−7.9EPS, diluted−0.51Fiscal year 2025Net income−10.4EPS, diluted−1.35
FY2022FY2023FY2024FY2025
Net income −7.1 −12.0 −7.9 −10.4
Growth
EPS, diluted −0.40 −0.85 −0.51 −1.35
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−5.6Fiscal year 2023Operating cash flow−4.5Fiscal year 2024Operating cash flow−5.6Fiscal year 2025Operating cash flow−4.7
FY2022FY2023FY2024FY2025
Operating cash flow −5.6 −4.5 −5.6 −4.7

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Shareholders’ equity−0.6Fiscal year 2023Shareholders’ equity4.4Fiscal year 2024Cash2.8Shareholders’ equity2.2Fiscal year 2025Cash6.3Shareholders’ equity10.4
FY2022FY2023FY2024FY2025
Cash n/a n/a 2.8 6.3
Shareholders’ equity −0.6 4.4 2.2 10.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −273.9% −357.0% −100.5%
−822.6% −242.9% −268.6% −94.1%
Balance and payout
169.5% 11.3% 24.7% 6.3%